U.S. flag

An official website of the United States government

GRCh37/hg19 1q22(chr1:155864518-156213257)x3 AND not provided

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
May 24, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003484043.1

Allele description [Variation Report for GRCh37/hg19 1q22(chr1:155864518-156213257)x3]

GRCh37/hg19 1q22(chr1:155864518-156213257)x3

Genes:
  • KHDC4:KH domain containing 4, pre-mRNA splicing factor [Gene - OMIM - HGNC]
  • PMF1-BGLAP:PMF1-BGLAP readthrough [Gene - HGNC]
  • RAB25:RAB25, member RAS oncogene family [Gene - OMIM - HGNC]
  • RIT1:Ras like without CAAX 1 [Gene - OMIM - HGNC]
  • ARHGEF2:Rho/Rac guanine nucleotide exchange factor 2 [Gene - OMIM - HGNC]
  • BGLAP:bone gamma-carboxyglutamate protein [Gene - OMIM - HGNC]
  • LMNA:lamin A/C [Gene - OMIM - HGNC]
  • LAMTOR2:late endosomal/lysosomal adaptor, MAPK and MTOR activator 2 [Gene - OMIM - HGNC]
  • MEX3A:mex-3 RNA binding family member A [Gene - OMIM - HGNC]
  • PMF1:polyamine modulated factor 1 [Gene - OMIM - HGNC]
  • PAQR6:progestin and adipoQ receptor family member 6 [Gene - OMIM - HGNC]
  • RXFP4:relaxin family peptide/INSL5 receptor 4 [Gene - OMIM - HGNC]
  • SEMA4A:semaphorin 4A [Gene - OMIM - HGNC]
  • SSR2:signal sequence receptor subunit 2 [Gene - OMIM - HGNC]
  • SLC25A44:solute carrier family 25 member 44 [Gene - OMIM - HGNC]
  • UBQLN4:ubiquilin 4 [Gene - OMIM - HGNC]
Variant type:
copy number gain
Cytogenetic location:
1q22
Genomic location:
Chr1: 155864518 - 156213257 (on Assembly GRCh37)
Preferred name:
GRCh37/hg19 1q22(chr1:155864518-156213257)x3
HGVS:

    Condition(s)

    Synonyms:
    none provided
    Identifiers:
    MedGen: C3661900

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...

    Assertion and evidence details

    Submission AccessionSubmitterReview Status
    (Assertion method)
    Clinical Significance
    (Last evaluated)
    OriginMethodCitations
    SCV004230815Quest Diagnostics Nichols Institute San Juan Capistrano
    criteria provided, single submitter

    (ACMG/ClinGen CNV Guidelines, 2019)
    Uncertain significance
    (May 24, 2023)
    unknownclinical testing

    PubMed (1)
    [See all records that cite this PMID]

    Summary from all submissions

    EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
    not providedunknownunknownnot providednot providednot providednot providednot providedclinical testing

    Citations

    PubMed

    Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen).

    Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, Raca G, Ritter DI, South ST, Thorland EC, Pineda-Alvarez D, Aradhya S, Martin CL.

    Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6. Erratum in: Genet Med. 2021 Nov;23(11):2230. doi: 10.1038/s41436-021-01150-9.

    PubMed [citation]
    PMID:
    31690835
    PMCID:
    PMC7313390

    Details of each submission

    From Quest Diagnostics Nichols Institute San Juan Capistrano, SCV004230815.1

    #EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
    1not providednot providednot providednot providedclinical testing PubMed (1)
    #SampleMethodObservation
    OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
    1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

    Last Updated: Feb 4, 2024